Using untargeted metabolomics in both in vitro models and patient samples, we characterized the metabolic landscape driven by MYCN in NB and identified key metabolic nodes relevant to NB patients and suitable for therapeutic intervention. The gene discussed is MYCN; the disease is neuroblastoma.